AbbVie and International Myeloma Foundation announce partnership
AbbVie and the International Myeloma Foundation Announce Partnership
MSD and Sun enter generics partnership
MSD and Sun Pharmaceutical Industries have entered into a joint venture to bring branded generics to emerging markets. The partnership will see...
Latest articles
Greater global collaboration: Time to focus on science and not geography
The Pistoia Alliance is urging industry stakeholders worldwide to focus on science and not geography, in a call for greater global collaboration. More than 250...
Accelerating the MedTech landscape
The Academic Health Science Networks (AHSN) in partnership with the Association of British HealthTech Industries (ABHI) has launched a report on accelerating the MedTech...
Tescaro present data on dostarlimab in endometrial cancer
Tescaro release positive results from the GARNET study on dostarlimab in endometrial cancer. TESARO, an oncology-focused business acquired by GlaxoSmithKline plc, presents data from the...
Popular articles
AUGUSTUS trial demonstrates favourable safety results
The Bristol-Myers Squibb-Pfizer Alliance has announced results from the Phase 4 AUGUSTUS trial evaluating Eliquis ® (apixaban) versus vitamin K antagonists (VKAs) in patients...
Digital partnerships in pharma and the NHS
Can pharma and the NHS equal the fast pace of change necessary to fully embrace technological innovation? Over the last few years, slowly but surely,...
Analysis of trial results of Brilinta for heart attack patients following thrombolysis
Analysis of trial results of Brilinta for heart attack patients following thrombolysis shows it met safety endpoint in secondary analysis of Phase III TREAT trial. The secondary...
The future of genomics and precision medicine
How is the use of genomics data enhancing our medical understanding and what does this mean for the future of precision medicine? Genomics is one of...
Trial sub-analyses support CV effects of Farxiga in T2D
Positive results from a pre-specified sub-analysis of the Phase III DECLARE-TIMI 58 trial showed that Farxiga (dapagliflozin) reduced the relative risk of major adverse...